Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
about
An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Identification of the mechanism of action of a glucokinase activator from oral glucose tolerance test data in type 2 diabetic patients based on an integrated glucose-insulin model.Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolismMechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetesLiraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysisBeyond insulin replacement: addressing the additional needs of the diabetes patient.Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog.Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.Liraglutide: clinical pharmacology and considerations for therapy.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure.Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic ratsThe Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model.Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.Are GLP-1 receptor agonists useful against traumatic brain injury?
P2860
Q33786150-58D48CFA-10E2-4B8F-944D-1D83731A8593Q34102632-03299810-E0A9-45AD-B960-AF386FAE0F90Q35801801-9FBF65E2-6DC6-4D99-AD87-86A375BB9E30Q35876818-9046E227-1911-41E6-B447-85188820543EQ36017369-0F9D1760-B58D-4816-921A-42323A28FBF2Q36139090-E2771CEB-2DA0-4C26-A7DA-3377EF81C97DQ36520655-1166D80D-2A1F-420E-B1D3-FC6E8A1559C0Q37199333-5752FCBB-D861-46F8-9B4D-BCEC8EC7DF73Q37348394-F8A5EF82-F580-4D60-A572-93F85C14F302Q37641326-5B066A84-03CB-49B1-8D2F-B622530B9E54Q37872358-997AD5DB-5462-45A7-8CF9-93AE9E554491Q37933408-7274648B-7746-4274-9D5F-58C4987363DDQ38110433-0EFD16FC-276B-45F9-BE33-37635920FC03Q38202156-9C5A6764-EAE7-46F6-84CB-9261A85239FBQ38213037-2D294BF9-0B49-4D71-A581-AFE84DD62B11Q39276306-D5495A05-B261-427C-9135-7DE819E184C1Q40678970-C423ABD5-4281-4C1E-A13B-345392DAA087Q46677274-7B10D1C7-68A3-4780-923F-23898D9DFEB6Q50718537-9B62DF26-7B42-4892-B5CA-7F3A144861B7
P2860
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
@en
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
@nl
type
label
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
@en
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
@nl
prefLabel
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
@en
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
@nl
P1476
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
@en
P2093
Henrik Agersø
Paolo Vicini
P304
P356
10.1016/S0928-0987(03)00073-3
P407
P577
2003-06-01T00:00:00Z